Laurus Labs Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Laurus Labs Ltd. authored by KRChoksey and published by - Trendlyne research reports.
Item: Laurus Labs Ltd.
Rating: 4
Author: KRChoksey

Keep track of all breaking news and updates on Laurus Labs Ltd. from all sources in a single place.

Load latest

Laurus Labs Ltd.

27 Jan 2025

628.05

0.18%

Company Update

Laurus Labs Ltd - 540222 - Clarification sought from Laurus Labs Ltd

BSE India

The Exchange has sought clarification from Laurus Labs Ltd on January 27, 2025, with reference to news appeared in https://www.cnbctv18.com/ dated January 27, 2025 quoting "Here is why Laurus Labs shares are down 15% on Monday" The reply is awaited.

Laurus Labs Ltd.

27 Jan 2025

628.05

0.18%

Late stage projects and high value API to drive growth

Accumulate: Laurus Labs Ltd.

Target

KRChoksey

Laurus Labs’ revenue beat our estimates significantly due to strong growth in Custom Synthesis segment and FDF segment. EBITDA beat our estimates due to better-than-expected gross profit and Adj. PAT beat our estimates due to strong operating performance.

Laurus Labs Ltd. has gained 45.58% in the last 1 Year

Laurus Labs Ltd.

27 Jan 2025

628.05

0.18%

Laurus Labs (SELL): Margin guidance shifted from 20% to closer to 20% for FY25E

Sell: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Revenue/EBITDA/PAT exceeded our estimates by 10.5%/46.6%/227%. EBITDA margin surpassed our estimate by 500bps

Laurus Labs Ltd. has an average target of 587.75 from 4 brokers.

Laurus Labs Ltd.

25 Jan 2025

628.05

0.18%

Laurus Labs Q3 Results 2025: Profit Soars 298.88% Year-on-Year

livemint

Laurus Labs Q3 Results 2025 on 25 Jan, 2025: Revenue increased by 18.42% YoY & profit increased by 298.88% YoY, profit at 92.3 crore and revenue at 1415.05 crore.

Laurus Labs Ltd. has an average target of 587.75 from 4 brokers.

Laurus Labs Ltd.

25 Jan 2025

628.05

0.18%

Beat on earnings; green shoots visible

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab (LAURUS) significantly beat our earnings estimates in 3QFY25, led by a scale-up in the CDMO segment. Commercial supplies (including launch quantities) led to strong 89% YoY growth in CDMO sales for the quarter.